HomeNewsIndiaCOVID-19 impact: Amway India gears up to meet increased demand for immunity, nutrition products

COVID-19 impact: Amway India gears up to meet increased demand for immunity, nutrition products

The company, which is taking a look at its "portfolio in a big way" in India as part of planned global investments, is studying how to readjust the portfolio more towards immunity and nutrition here in the country.

May 17, 2020 / 10:44 IST

With increased demand for immunity and nutrition products during the coronavirus lockdown, direct selling major Amway is gearing up for enhanced focus on the category and expecting up to 65 percent of its total business to come from it going forward, a top company official said.

The company, which is taking a look at its "portfolio in a big way" in India as part of planned global investments, is studying how to readjust the portfolio more towards immunity and nutrition here in the country.

Amway India also expects its business to come back to at least 80-90 percent of pre-lockdown levels by July.

During the lockdown, a consumer trend has been observed with demand moving towards immunity and nutrition products, Amway India CEO Anshu Budhraja told PTI.

"People are more attuned to consuming for their own self-care...During the lockdown the classic case is that people did not want to go to hospital, otherwise people earlier wanted to go to doctors for true curative (treatment). People have now moved to preventive and they see see value in preventive," he said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Therefore, he said, "the need for supplementation is leading to the heightened awareness for stronger immunity. I think that is one big mega trend which we see. We have coined the term 'What's IN' and IN stands for immunity and nutrition."

Budhraja further said the emerging consumer trend is also "helping our ayurveda line" in which the company has six stock keeping units (SKUs) out of which tulsi-based supplement saw a huge demand.

Asked if the company would ramp up production of such immunity and nutrition products, he said, "Good companies always follow consumer demands and consumer needs. If consumer demands and needs towards immunity supporting range goes up, obviously we will support that."

Predicting that this market will grow over a period of time, he said, "It will grow more than the market in beauty (category) in the mid-term at least. We do see a mix change in our portfolio where immunity and nutrition will move up to almost 60-65 percent of the total business as compared to almost 56 percent at present."

He further said,"We envisage that these categories will grow at a much faster pace because consumer is evolving and naturally inclined to migrate into those segment."

Reiterating the company's focus on the segment as part of planned global investments, Budhraja said, "We are looking at portfolio in a big way, how we can readjust our portfolio more towards immunity and nutrition. We are looking at multiple things around that."

Commenting on business resmuption after the lockdown, Budhraja said after being immediately impacted, operations of the company are scaling back gradually to achieve business continuity.

The company's plant in Tamil Nadu has already been producing immunity and nutrition products which were included in essential items category, although beauty and home durable products were impacted.

Out of 140 shops that Amway has in India, 90 percent are open and a similar percentage of warehouses have also started functioning following government guidelines. Offices are also back with 33 percent of employees, he added.

"We have achieved business continuity in 60 days. After 90 days we will try and see how fast we can come back. By July I do expect us to come back to at least 80-90 percent of where we were in pre-lockdown,"he said.

PTI
first published: May 17, 2020 10:25 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347